Chemical targeting of individual components of the UHRF1-DNMT1-G9a complex has already been investigated in liver cancers as a therapeutic strategy, such as the DNMT inhibitor decitabine45 and the G9a inhibitor BIX-01294,46 and showed only limited effects on cell viability when given as monotherapy. The gene discussed is EHMT2; the disease is liver cancer.